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Interferon-based treatments have a poor safety proﬁle and lim-
ited efﬁcacy in patients with advanced liver disease and in
patients with hepatitis C (HCV) recurrence after liver transplanta-
tion (LT). Despite the recent approval of the ﬁrst interferon-free
regimen, which will be followed by several other interferon-free
combinations in 2014 and 2015, data in patients with advanced
cirrhosis and hepatitis C after LT are still limited. One study has
already proven the concept that graft HCV infection can be pre-
vented in a signiﬁcant proportion of patients by treating them
with sofosbuvir and ribavirin while awaiting LT. Two inter-
feron-free regimens have also demonstrated a high efﬁcacy in
patients with hepatitis C recurrence after transplantation. Before
these treatment strategies can be implemented in clinical prac-
tice, a few issues need to be addressed: (1) safety and efﬁcacy
of new antivirals in patients with decompensated cirrhosis, (2)
the impact of viral clearance on liver function, (3) the potential
consequences of virological failure (and the selection of multi-
drug resistant HCV strains) in patients with decompensated
cirrhosis or with severe hepatitis C recurrence after LT, and (4)
drug-drug interactions (DDI) proﬁles. Finally, in the transplantJournal of Hepatology 20
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cost-effective in minimizing the negative impact of hepatitis C:
preventing graft infection by treating patients before transplanta-
tion or treating hepatitis C recurrence after LT.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
In the last year, the approval of the ﬁrst interferon-free regimens
for the treatment of chronic hepatitis C has been a major step for-
ward in hepatology. The safety and efﬁcacy of the combination of
several direct-acting antivirals (DAAs), compared to interferon-
containing regimens [1], has opened hope for groups of patients
in whom interferon-based regimens were contraindicated or in
whom these regimens had a very limited efﬁcacy and poor toler-
ance. In particular, the negative impact of hepatitis C recurrence
on graft and patient survival following LT [2,3] makes gaining
information on how to treat these patients urgent.
There are three well-deﬁned groups of individuals for which
there is an urgent need to assess the safety and efﬁcacy of inter-
feron-free regimens: (1) patients awaiting liver transplantation,
(2) patients with decompensated cirrhosis not included in a wait-
ing transplant list and; (3) individuals with hepatitis C recurrence
after transplantation.Management of patients awaiting liver transplantation
Patients with advanced cirrhosis, particularly those awaiting LT,
are one of the most difﬁcult-to-treat population. The main aim
of antiviral treatment for patients on the waiting list is to prevent
HCV infection of the new liver, since HCV recurrence reduces
graft and patient survival. Most centres indicate short term ther-
apy in order to achieve undetectable HCV-RNA at LT, which is
associated with a high chance of preventing graft infection
following transplantation [4]. In a setting of shorting organ
availability, a second potential aim is to improve liver function,
and perhaps regain compensation for ﬁnally delisting. This has
been shown in some patients with HBV-related cirrhosis treated
with nucleo(s)tide analogues [5,6], but in HCV-infected cirrhotic
patients this has not been demonstrated [7].14 vol. 61 j S120–S131
Key Points
• Treatment with IFN-free regimens will prevent hepatitis 
C recurrence in a significant proportion of patients 
with compensated cirrhosis and hepatocellular 
carcinoma awaiting LT. The best treatment regimen 
in this scenario is still not defined, but most likely will 
consist of the combination of sofosbuvir with a second 
DAA (daclatasvir, ledipasvir, simeprevir depending on 
the HCV genotype). In areas where these drugs are 
not available, IFN-based regimens may still prevent 
hepatitis C recurrence in a small proportion of patients.
• Patients with decompensated cirrhosis cannot undergo 
IFN-based regimens. Data on safety and efficacy of 
IFN-free regimens in this population are very limited 
and thus, recommendations are not supported by data. 
In decompensated cirrhotic patients awaiting LT, IFN-
free regimens may allow viral clearance and prevent 
hepatitis C recurrence. In addition, viral clearance may 
be associated with liver function improvement, keeping 
some patients away from LT (with a better use of this 
valuable resource). Pharmacokinetics and safety data 
in this patient population are available for sofosbuvir, 
simeprevir  and daclatasvir.
• In decompensated cirrhotic patients not enlisted for 
transplantation, treatment with IFN-free regimens 
should aim at reducing clinical events and particularly 
at improving survival. Treatment in this population 
might be considered in cases without life-threatening 
comorbidities. Nevertheless, well designed trials are 
necessary to address the clinical benefit of treating this 
population.
• IFN-free regimens should be the goal for individuals 
with severe hepatitis C recurrence after LT. Early 
treatment of individuals with aggressive HCV 
recurrence may allow for a full recovery of liver function 
and fibrosis regression. 
• In liver transplant recipients with decompensated 
cirrhosis IFN-free regimens may be associated with 
improvement in liver function in some patients. In those 
who do not improve, retransplantation might become 
a choice in the case of a high MELD score and HCV 
clearance.
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Fig. 1. Efﬁcacy results of IFN-based therapies in cirrhotic patients. SOF + PR,
sofosbuvir plus PegIFN and RBV during 12 weeks, genotype 1 (NEUTRINO study
[21]). SMV + PR, simeprevir (12 weeks) plus PegIFN and RBV (24–48 weeks),
genotype 1 (pooled data of QUEST-1 [22], QUEST-2 [23], PROMISE [24], ASPIRE
[25], and ATTAIN studies [26]). DCV + PR: daclatasvir (12–24 weeks) plus PegIFN
and RBV (24–48 weeks), genotypes 1 and 4 (COMMAND-1 study) [27].
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Current interferon-based treatments are not optimal in patients
with advanced cirrhosis. Some studies have shown that peginter-
feron (PegIFN) plus ribavirin (RBV) administered to patients on
the waiting list can prevent graft infection in patients who
achieve undetectable HCV RNA [4,8–10]. Virological responses
maintained after LT are around 25%, even when using a low accel-
erating dose regimen (LADR) [10]. Sustained virological response
(SVR) rates are higher in individuals infected with HCV genotypes
2 and 3, as well as in those with the IL28B CC genotype [11]. Nev-
ertheless, interferon-based therapy can only be administered in
cirrhotic patients with good liver function (Child-Pugh 67 or
MELD 618), in whom the indication of transplantation is hepato-
cellular carcinoma (HCC) [3]. A recent study including livingJournal of Hepatology 2014donor liver transplantation recipients and patients with HCC with
MELD exception points (typically patients with better liver func-
tion) demonstrated SVR rates around 50% if pre-transplant ther-
apy lasted >16 weeks [9]. In patients with more advanced
disease, serious adverse events (i.e., bacterial infections, such as
spontaneous bacterial peritonitis or spontaneous bacteraemia
[8], grade 3 and 4 cytopenias and clinical decompensation) are
frequent and can be life-threatening. Thus, only a small propor-
tion of HCV-infected patients can undergo interferon-based
treatment.
The addition of ﬁrst-generation protease inhibitors (PIs),
boceprevir and telaprevir, to PR is clearly associated with an
increase in response rates in G1 infected patients [12–16], includ-
ing some patients awaiting LT. Verna et al. [17] reported the
results of triple therapy in a small cohort of HCV-infected
cirrhotic patients (n = 29) on the waiting list for LT (Child-Pugh
A 62%, Child-Pugh B 38%). The median duration of treatment
was 27 weeks. Post-transplant SVR12 was 67% (8 out of 12 trans-
planted patients). From a perspective of safety, serious adverse
events occurred in nine patients (31%), including one death
(3%) and 8 hospitalizations (28%). Despite these results, the pro-
portion of patients on the waiting list that may beneﬁt from triple
therapy with telaprevir or boceprevir is small, for several reasons.
First, in decompensated patients (Child-Pugh C) IFN-based thera-
pies are contraindicated. Second, SVR rates are very low in
cirrhotic patients who are previous null-responders to PR (a com-
mon situation in patients awaiting LT). Third, PI-based regimens
in real-life compensated cirrhotic patients are associated with
serious adverse events (SAEs), such as severe infections (4–6%),
clinical decompensation (3–4%) and even death [18,19]. Patients
with a platelet count below 100,000/mm3 and serum albumin
levels below 35 g/L have a higher risk than 40% to life-threatening
side effects [18].
More importantly, with the recent approval of sofosbuvir,
simeprevir and daclatasvir, the use of boceprevir and telaprevir
should not be recommended in this population [20]. Despite
not having data on the efﬁcacy of PR combined with new DAAs
in patients awaiting LT, studies assessing these combinations
which include a sufﬁcient number of patients with cirrhosis, sug-
gest good safety and efﬁcacy in individuals with well-compen-
sated disease in whom the indication for LT is HCC. SVR rates
in cirrhotic patients treated with PR plus simeprevir (SMV),
daclatasvir (DCV) and sofosbuvir (SOF) are summarized in Fig. 1vol. 61 j S120–S131 S121
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[21–27]. The combination of PR plus sofosbuvir for 12 weeks
seems to offer the highest efﬁcacy and the best safety proﬁle: this
regimen was evaluated in the NEUTRINO phase 3 trial in treat-
ment-naïve G1, 4, 5, and 6 patients (most G1) [21]. The overall
SVR rate was 90%: cirrhotic patients had a lower sustained viro-
logic response (SVR) rate than non-cirrhotic patients (80% vs. 92%,
respectively). Regretfully, data in treatment-experienced cir-
rhotic patients using this combination, are only available in a
small number of G2 and G3 infected patients, with SVR rates over
80% [28].
Interferon-free regimens in patients awaiting LT
Sofosbuvir and ribavirin in patients awaiting LT
In a phase 2 open-label study, 61 HCV-infected patients (G1–4)
awaiting LT, received sofosbuvir and ribavirin until transplanta-
tion or up to 48 weeks [29]. The indication for LT was HCC; nearly
75% of patients were Child-Pugh A, all had MELD score below 15
and most individuals were previous non-responders to inter-
feron-based regimens (75%). The median duration of therapy
was 17 weeks.
Forty-six patients underwent LT and of these, 43 (92%) had
HCV RNA <25 IU/ml at time of LT. Of them, 42 reached 12 weeks
of follow-up after transplantation and 29 (69%) achieved SVR at
12 weeks after the end of therapy (SVR 12). The strongest predic-
tor of post-LT SVR was the number of consecutive days with
undetectable HCV RNA prior to transplant, with only one relapse
among the 25 individuals with undetectable HCV-RNA for
>28 days while on treatment. Treatment with SOF + RBV was
generally well tolerated. The most frequently reported adverse
events were mild, and only 1 patient discontinued treatment
due to anaemia. These efﬁcacious results are encouraging. Longer
treatment duration and/or the addition of a second DAA (cur-
rently under evaluation with ledipasvir [LDV]), may reduce the
rate of virological relapse.
Future interferon-free regimens in patients awaiting LT
In most phase 2 and registration trials, the proportion of
cirrhotics is small and those with clinically signiﬁcant portal
hypertension are usually excluded. The data available so far are
not enough for indicating IFN-free regimens to all patients await-
ing a transplant, particularly for decompensated cirrhotics. How-
ever, patients with platelet counts above 50,000–60,000/mm3
(and thus with signiﬁcant portal hypertension) were included
in a few trials and safety and efﬁcacy results were still good
(Tables 1 and 2). The available data support the use of IFN-free
regimens in patients with compensated cirrhosis and hepatocel-
lular carcinoma awaiting LT.
For genotype 1 cirrhotic patients, the combination of sof-
osbuvir and ribavirin appears suboptimal, particularly in previ-
ous non-responders. Data from phase 2 studies [30,31]
strongly suggest that the addition of simeprevir or daclatasvir
to sofosbuvir (with or without ribavirin) signiﬁcantly increases
SVR rates up to 90% (Table 1). The data are yet to be conﬁrmed
in clinical trials including a larger number of cirrhotic patients
(Table 2).
Two registration phase 3 studies have assessed the safety and
efﬁcacy of sofosbuvir and ledipasvir (with or without ribavirin)
for 12 vs. 24 weeks in G1 infected patients [32,33]. In the ﬁrst
study (ION-1), which included naive patients, there were 136 cir-
rhotic patients and SVR rates were 100% in the RBV arms and 97%S122 Journal of Hepatology 2014in the non-RBV arms (Fig. 2A). In the second study (ION-2), which
included treatment-experienced patients (with a signiﬁcant
number of failures to PI), there were 88 cirrhotic patients: SVR
rates were 100% in the 24-week regimen, but the ﬁgure
decreased to 85% in the 12-week arms (Fig. 2A). The latter sug-
gests that a regimen containing sofosbuvir and ledipasvir is
excellent in compensated cirrhotics; extension to 24 weeks may
be necessary in previous non-responders.
A large randomized clinical trial performed speciﬁcally in cir-
rhotic patients with an all-oral DAA combination [34] has
recently evaluated the safety and efﬁcacy of ABT-450 boosted
with ritonavir, ombitasvir, and dasabuvir co-administered with
RBV for 12 or 24 weeks in HCV genotype 1-infected patients
(both treatment-naïve and -experienced). SVR rates reached
92% and 96% in the 12-week and 24-week arms, respectively
(Fig 2A). A trend toward slightly lower SVR rates were observed
in G1a previous null-responders, as well as in patients with more
signiﬁcant portal hypertension (platelets <100,000/mm3) or more
advanced cirrhosis (albumin <35 g/L) in the 12-week arm.
Finally, a combination of daclatasvir and asunaprevir (ASV) for
24 weeks was evaluated in 223 genotype 1b cirrhotics; SVR rates
were 91% in treatment-naïve, 81% in ineligible/intolerant patients
and 87% in treatment-experienced individuals [35].
For genotype 2 and 3-infected patients, results from four
phase 3 trials assessing sofosbuvir plus ribavirin have been pub-
lished (Fig. 2B). Overall, SVR rates in G2 were consistently lower
in cirrhotic patients compared to non-cirrhotics, but 12 or 16-
week regimens achieved SVR rates of around 80%. Regarding
genotype 3, it became clear that a 12-week regimen of sofosbuvir
and ribavirin was insufﬁcient for cirrhotic patients [21], in whom
treatment extension up to 24 weeks increased SVR rates up to
92% in treatment-naïve patients and to 61% in previous non-
responders to PR [36] (Fig. 2B). For G4-infected patients there is
very little data on interferon-free regimens, and no solid recom-
mendations can be given in case of cirrhosis [20].
Speciﬁc features of interferon-free regimens in patients awaiting LT
With the current approval of sofosbuvir, simeprevir and daclatas-
vir in the US and Europe, interferon-free regimens are being used
in those cirrhotic patients with compensated liver disease await-
ing LT. In patients with decompensated liver disease, on the wait-
ing list for LT, safety and efﬁcacy data are still lacking and thus no
clear recommendations can be given.
In any case, there are some distinct features that should be
taken into consideration in individuals awaiting LT. The primary
goal of treatment in these patients is to prevent HCV graft infec-
tion. Since the main source of virions (if not all) will be removed,
this may be accomplished by a short course of antiviral therapy
[29]. As shown above, sofosbuvir and ribavirin seem to be a good
choice in this setting. There are, however, some problems associ-
ated with this strategy: (1) timing of treatment is difﬁcult (when
to start?), (2) there is the possibility of post-LT relapse, and (3) if
a second DAA is added, there are no safety data in Child-Pugh B
and Child-Pugh C patients and pharmacokinetic studies are not
available for all drugs (Table 3). A second approach for treating
patients on the waiting list may be to complete a full treatment
course to achieve SVR, not only to prevent graft infection but to
assess if liver function improves. In some patients without HCC,
the improvement in liver function and/or portal hypertension
could imply delisting. In others, however, improvement may
not occur or may be insufﬁcient for avoiding LT.vol. 61 j S120–S131
Table 1. Phase 2 clinical trials with IFN-free regimens including cirrhotic patients.
Therapeutic regimen 
in trial arm including 
cirrhotic population
(trial name)
Response to 
previous IFN based 
therapy
Lower 
limit of 
platelets
(mm3)
Treatment 
duration in 
the specific 
arm (wk)
Cirrhotic patients 
enrolled in the 
study
N (%)
Genotype
spectrum
SVR in cirrhotic patients
SOF + RBV
NIH SPARE [94]
Naïve 75,000 24 13 (26)
F3-4
1
(G1a 70%)
SVR24
50% and 29%
(weight-based and low-dose 
RBV respectively)
SOF + RBV or
GS-0938 or
GS-0938 + SOF 
(± RBV)
(QUANTUM) [95]
Naïve 50,000 12
24
21 (9) 1-4 SVR12 
50%
(SOF + RBV arm, 24 wk)
SOF + LDV ± RBV
(6th and 7th arms)
(ELECTRON) [96]
Null-responder n.s. 12 19 (100) 1 SVR12
100% and 70%
(with and without RBV 
respectively)
SOF + LDV ± RBV 
(Cohort B)
(LONESTAR) [97]
Non-responder to 
protease inhibitor 
regimen
n.s. 12 22 (55) 1
(G1a 85%)
SVR12
100% and 95%
(with and without RBV 
respectively)
SOF + LDV
(arm A)
(NIAID SYNERGY) [98]
Naïve 50,000 12 3 (15) 1
(G1a 55%)
SVR12 
100%
SMV + SOF ± RBV 
(Cohort 2)
(COSMOS) [30]
Naïve and null- 
responder
n.s. 12
24
41 (25) 1
(G1a 78%)
SVR12
91% null-responders (21/33)
94% naïve (17/18)
DCV + ASV 
+ BMS-791325 [99]
Naïve n.s. 12 15 (9) 1
(G1a 86%)
SVR12
71% and 100% with 75 mg 
and 100 mg of BMS-791325 
respectively
FDV + DBV ± RBV
(SOUND C2) [100]
Naïve 90,000 16, 28, 40 33 (9) 1 SVR12
33%-67%
according to different 
regimen
FDV + DBV + RBV
(SOUND C3) [101]
Naïve 75,000 16 4 (20) 1 SVR12
100%
SOF + DCV ± RBV
(A1444040) [31]
Naïve and treatment- 
experienced (also to 
protease inhibitors)
n.s. 12
24
32 (15) 1-3 SVR12
100%
SOF/LDV FDC ± RBV
(ELECTRON-2) [102]
Naïve and treatment- 
experienced
50,000
(CTP-A)
12 20 (100) G1* 
8 (16) in G3
1,3 SVR12 G1 65%
SVR12 G3 100% in LDV/
SOF + RBV arm
MK-5172 + MK-8742 
± RBV
(WORTHY) [103]
Null-responder 70,000 12
18
123 (100) naïve 
and 51 (39) in NR
1 SVR8 94 and 100% in 
G1a and G1b respectively 
(both naïve and treatment- 
experienced)
SOF + RBV [39]* Naïve and treatment- 
experienced
n.s. 48 50 (100) 1-4 Week 24 of therapy
HCV-RNA <LLOQ
100% and 93% in CTP A 
and B respectively
⁄Including patients with decompensated cirrhosis.
n.s., no speciﬁed platelet lower limit.
wk, weeks; G, genotype; CTP, Child-Pugh; SVR12, sustained virologic response 12 weeks after the end of treatment; SVR24, sustained virologic response 24 weeks after the
end of treatment.
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JOURNAL OF HEPATOLOGYA second distinct feature, particularly in those with decom-
pensated disease, is the impact of liver function on drug pharma-
cokinetics (PK): metabolic liver functions are signiﬁcantly
involved in the total clearance of a number of drugs. PK studies
in patients with liver disease are an important clinical pharma-
cology component of drug development [37]. PK data on a num-
ber of new antivirals are already available and summarized in
Table 3.Journal of Hepatology 2014As an example, exposure to sofosbuvir was 2-fold higher in
HCV-infected patients without hepatic impairment, as compared
to patients with advanced liver disease. The latter group experi-
enced a less profound viral decline than those with normal liver
function when sofosbuvir was administered [38]. These data,
supported by a recent study performed in decompensated cirrho-
tics [39], may have clinical consequences and explain why in
patients with advanced liver disease longer treatment durationvol. 61 j S120–S131 S123
Table 2. Phase 3 clinical trials with IFN-free regimens including cirrhotic patients.
Therapeutic regimen 
in trial arm including 
cirrhotic population
(Trial name)
Response to 
previous IFN based 
therapy
Lower 
limit of 
platelets
(mm3)
Treatment 
duration in 
arm (wk)
Cirrhotic patients 
enrolled in the 
study
N (%)
Genotype
spectrum
SVR in cirrhotic patients
SOF + RBV [104] Naïve and treatment- 
experienced
n.s. 12
24
14 (23) 4 SVR12
79% and 100% in naïve
59% and 87% in treatment-
experienced
(12 and 24 wk respectively)
DCV + ASV + 
BMS-791325 [105]
Naïve n.s. 12 2 (10) 4 SVR12 
100%
SOF + RBV
(FISSION) [21]
Naïve 75,000 12 50 (20) 2, 3 SVR12 
47%
SOF + RBV
(POSITRON) [106]
IFN intolerant No lower 
limit
12 31 (15) 2, 3 SVR12 
61%
(G2 94% and G3 21%)
SOF + RBV
(FUSION) [106]
Non-responder 50,000 12
16
36 (35)
32 (33)
2, 3 SVR12
G2 60% and 78%
G3 19% and 61%
(12 and 16 wk respectively)
SOF + RBV
(VALENCE) [36]  
Naïve and treatment-
experienced
50,000 12   G2
24   G3
10 (14) G2
59 (22) G3
2, 3
(G3 78%)
SVR12 
G2 100% and 88%
G3 92% and 60%
(naïve and treatment- 
experienced respectively)
LDV/SOF ± RBV
(ION-1) [32]
Naïve 50,000 12
24
136 (16) 1 SVR12 97 and 100% ± RBV 
(both 12 and 24 wk)
LDV/SOF ± RBV
(ION-2) [33]
Treatment- 
experienced
50,000 12
24
88 (20) 1 SVR12 82-86% 12 wk arm 
(± RBV) and 100% 24 wk 
arm
DCV + ASV [107] IFN ineligible naïve/
intolerant and non-
responder
n.s. 24 22 (10) 1b SVR24 
90.9%
DCV + ASV 
(HALLMARK-DUAL) 
[35]
Naïve, IFN ineligible/
intolerant and non-
responder
n.s. 24 223 (30) 1b SVR12
91%, 87% and 81% in 
naïve, non-responders 
and  ineligible/intolerant 
respectively
ABT-450/r + ombitasvir + 
dasabuvir + RBV
(TURQUOISE II) [34]
Naïve and treatment- 
experienced
60,000 12
24
380 (100) 1 SVR12 
91.8% and 95.9% in 12 and 
24 wk
the specific
n.s., no speciﬁed platelet lower limit; W, weeks; G, genotype; CTP, Child-Pugh; SVR12, sustained virologic response 12 weeks after the end of treatment; SVR24, sustained
virologic response 24 weeks after the end of treatment.
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Journal of Hepatology Update: Hepatitis Ccould be necessary to reduce the rates of virological relapse. From
a safety point of view, exposure to some new compounds (such as
ABT450/r) is signiﬁcantly increased in Child-Pugh C patients and
its use is currently not recommended. Adjustment of simeprevir
is not required in Child-Pugh class A or B patients [40], but par-
ticular caution is recommended when prescribing simeprevir to
HCV-infected patients with moderate or severe hepatic impair-
ment since no studies in HCV-infected individuals are available
yet. In patients with severe hepatic impairment (Child-Pugh class
C) simeprevir exposure is signiﬁcantly increased and should be
avoided [40] (Table 3).
A third distinct feature of patients awaiting LT is the poten-
tial risk of viral breakthrough or relapse during or after treat-
ment, which may theoretically induce ﬂares that could trigger
liver decompensation. It is thus very relevant to choose the
best treatment combination (high potency and high geneticS124 Journal of Hepatology 2014barrier) in order to minimize the possibility of virological
relapse or the selection of resistant-associated viral strains
(RAVs). S282T is the only variant shown to confer reduced sus-
ceptibility to sofosbuvir in vitro, but it has not been detected in
patients after virological failure. Differently, resistance to NS5A,
non-nucleotide NS5B and NS3 protease inhibitors are fre-
quently detected in individuals with virological failure. The ﬁt-
ness of resistant strains is usually lower than that of the wild-
type viruses, which tend to progressively replace RAVs. NS5A
RAVs, however, seem to persist for a long time. This is relevant,
since the presence of multi-resistant strains may hamper anti-
viral therapy if urgent treatment is required (such as in cases
of decompensated cirrhosis with virological relapse or severe
hepatitis C recurrence after LT). A nucleotide-based regimen
(such as sofosbuvir) appears to be the best salvage strategy
in such cases.vol. 61 j S120–S131
Naive
Treatment-exp. or IFN ineligible
G2 Naive
G2 Treatment-exp./IFN ineligible
G3 Naive
G3 Treatment-exp./IFN ineligible
0
20
40
60
80
100
SOF + LDV 
± RBV
DCV + ASV ABT-450/r/
O/D + RBV
13
2/1
34
81
/88
98%
92%
15
1/1
60
20
5/2
20
94% 93%91% 84%
29
/32
14
5/1
73
S
VR
12
 (%
)
A
B
0
20
40
60
80
100
12 12 16 12 24 12 16
83%
60%
78%
34%
92%
19%
61%
60%
10
/12 6/1
0 7/9
13
/38
12
/13 5/2
6
14
/23
24
27
/45
SOF + RBV (wk)
S
V
R
12
 (%
)
Fig. 2. Efﬁcacy results of phase 3 IFN-free therapies in cirrhotic patients
genotype-1 (A) and genotypes 2/3 (B). SOF + LDV: sofosbuvir plus ledipasvir
with or without ribavirin 12-24 weeks (ION-1 [32] and 2 [33]). DCV + ASV:
daclatasvir and asunaprevir for 24 weeks (only genotype 1b patients) [35]. ABT-
450/r/O/D: ABT-450 boosted with ritonavir plus ombitasvir, dasabuvir and
ribavirin 12-24 weeks [34]. SOF + RBV: pooled data of sofosbuvir plus ribavirin
12/16/24 weeks in the FISSION [21], FUSION [106] and VALENCE [36] studies.
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Table 3. Pharmacokinetics (change in AUC) of DAAs in hepatic impairment
(graded according to CTP score) and recommendation.
Drug CTP A 
(5-6 points)
CTP B 
(7-9 points)
CTP C 
(≥10 points)
Sofosbuvir [38,108] NR NPD NPD
Simeprevir [109]† NR NR AUC x 3
Daclatasvir [110, 111]¥ NR NR NR
Asunaprevir [112] NR AUC x 9.8 AUC x 32
Ledipasvir [113] NR NR NR
ABT-450/r [114]§ NR NR AUC x 11
Dasabuvir [114] NR NR NR
Ombitasvir [114] NR NR NR
MK-8742 [103] NR NR NPD
MK-5172 [103] NR NR NPD
NR, dose adjustment not required; NPD, no pharmacokinetic data or studies
ongoing.
AUC14 is given.
¥AUCtau is given.
§AUCinf is given.
JOURNAL OF HEPATOLOGY
Journal of Hepatology 2014Management of patients with decompensated cirrhosis
without an indication for LT
Patients with decompensated cirrhosis who are not candidates
for LT are usually the elderly or those in whom the presence of
comorbidities contraindicate a LT [41,42]. In these patients, the
only chance to improve or stabilize liver function is to eradicate
HCV with an interferon-free regimen. Indeed, in those individuals
without comorbidities impairing their life expectancy, HCV erad-
ication may be associated with clinical improvement and ﬁnally
with increased survival. Clinical trials in patients with decompen-
sated disease should include ‘‘hard’’ end points: improvement in
liver function, a decrease in clinical decompensation episodes
and an increase in survival.
However, the impact of SVR in patients with decompensated
cirrhosis may be heterogeneous, since it encompasses a wide
spectrum of disease, ranging from patients with relatively well-
preserved liver function (mild ascites or recent variceal bleeding)
to patients with very poor liver function and a short life expec-
tancy (Child-Pugh C >10 points) [43]. It is likely that in the latter
group viral clearance will not signiﬁcantly modify patients’ clin-
ical outcomes or survival. Nevertheless, only well-designed stud-
ies including appropriate control groups will be able to answer
these questions. Moreover, safety issues need to be carefully
addressed in this patient population.
Preliminary results of the ﬁrst study assessing the effect of
viral suppression on liver function were recently presented at
the EASL meeting (ILC 2014) [39]. In this study, cirrhotic patients
with documented portal hypertension and compensated or
decompensated cirrhosis (Child-Pugh 5–9 points) were random-
ized to sofosbuvir and ribavirin for 48 weeks vs. an observational
arm (after 6 months these patients crossed over to the treatment
arm). From a virological point of view, it was interesting to learn
that 2 and 4 weeks after treatment initiation 56% and 100% of
Child-Pugh A patients had undetectable HCV-RNA; ﬁgures for
Child-Pugh B patients were only 44% and 75%, respectively. This
might be particularly relevant in patients awaiting LT (see above)
where a short treatment course of therapy might not be sufﬁcient
to prevent post-LT relapse. After a 24-week period, the results
suggested a reduction of ascites and hepatic encephalopathy epi-
sodes in patients included in the treatment arm. However the
study was not blinded (and a bias when assessing clinical out-
comes cannot be excluded). More importantly, data on the effect
of treatment on portal pressure are not available yet.
There are several studies assessing interferon-free combina-
tions in patients with decompensated cirrhosis (Child-Pugh B
and C) (Supplementary Table 1).Treatment of hepatitis C recurrence after liver transplantation
HCV-related cirrhosis is the leading indication for LT in indus-
trialized countries [44]. Virological recurrence after transplan-
tation is constant in patients with detectable viraemia at the
time of LT [45]. The main characteristic of hepatitis C recur-
rence after LT is the accelerated course of the disease when
compared to immunocompetent patients [46–50]. Approxi-
mately one third of the patients progress to graft cirrhosis
within only 5 years after transplantation [51,52]. This acceleratedvol. 61 j S120–S131 S125
Table 4. Drug-drug interactions between DAAs and calcineurin inhibitors.
DAA Cyclosporine Tacrolimus
Healthy volunteers Dose adjustment Healthy volunteers Dose adjustment
Boceprevir [115, 116]¥ AUC ↑ 2.7 fold ↓ 2 fold AUC ↑ 17 fold ↓ 5 fold
Telaprevir [77, 117] ¥ AUC ↑ 4.6 fold ↓ 4 fold AUC ↑ 70 fold ↓ 35 fold
ABT450/r [86] AUC ↑ 5.8 fold ↓ 5 fold AUC ↑ 58 fold ↓ 100 fold
Simeprevir [118]§ AUC ↑ 19% Under investigation AUC ↓ 17% Not necessary
Sofosbuvir [119]¥ No change Not necessary No change Not necessary
Daclatasvir [120] No change Not necessary No change Not necessary
¥AUCinf is given.
§AUCLast is given.
T
re
a
tm
e
n
t
Journal of Hepatology Update: Hepatitis Cﬁbrosis rate impacts both the allograft and recipient survivals,
which are signiﬁcantly reduced when compared with non-HCV
LT recipients [46,50,51].
The effect of SVR on disease progression has been analysed
in large cohorts of non-immune compromised patients, com-
paring pre- and post-treatment liver biopsies. The data demon-
strate improvements in inﬂammation and ﬁbrosis scores
following SVR [53–60], although in a non-homogeneous pattern
(a subset of patients remains at the same stage, and some even
display persistent inﬂammation and/or ﬁbrosis progression)
[61]. The most important factor that determines ﬁbrosis regres-
sion after SVR is the baseline liver ﬁbrosis stage [60]. Actually,
the rate of cirrhosis regression has been estimated at 5–15%
after ten years [60,61]. Early cirrhosis might be more likely
to regress than established cirrhosis. Old ﬁbrous septa contain
high-density ﬁbrillar collagens (I and III) and proteoglycans,
pauci-cellularity and an increase in extracellular matrix (ECM)
cross-linking, which may contribute to the resistance to ﬁbrosis
regression [62–65]. Elastin, which accumulates in mature cir-
rhosis, is another non-collagenous matrix component that neg-
atively inﬂuences ﬁbrosis reversion [66,67]. Moreover, the
presence of established signiﬁcant portal hypertension may
also be determinant in ﬁbrosis irreversibility, since it is associ-
ated with an inﬂammatory state of the endothelium that in
turn, may activate hepatic stellate cells (HSCs) and ﬁbrogenesis
[68–70].
The information available in liver transplant patients is scarce,
but most likely these assumptions can be translated into LT
patients, particularly those who have developed cirrhosis over
the years. In patients who develop signiﬁcant ﬁbrosis (METAVIR
F P2) during the ﬁrst year, the situation may be different and
ﬁbrosis appears to be more reversible. Several studies have
shown a signiﬁcant histological improvement or stabilization
after SVR, in opposition to non-responders [71,72]. Similarly, por-
tal pressure measurements and determinations of transient elas-
tography also suggest a beneﬁcial effect of antiviral treatment on
liver ﬁbrosis when SVR is achieved [72]. Probably the most strik-
ing case is that of ﬁbrosing cholestatic hepatitis (FCH), where a
very early massive ﬁbrosis deposition can reverse if treated
promptly and viral clearance is achieved.
Interferon-based regimens to treat hepatitis C recurrence after LT
The most common approach to treat hepatitis C after LT has been
to start antiviral therapy once the histological damage (in partic-
ular liver ﬁbrosis) is conﬁrmed in the graft. The presence ofS126 Journal of Hepatology 2014signiﬁcant ﬁbrosis beyond the portal tract (METAVIR F P2), por-
tal hypertension (HVPG P6 mmHg) or high liver stiffness
(>8.7 kPa) one year after LT accurately identify patients at higher
risk for clinical decompensation and death [73,74], who are in
urgent need of treatment. In patients with a severe recurrence
occurring during the ﬁrst months after transplantation (i.e.,
FCH), antiviral therapy is critical, but IFN-based regimens are
unable to eradicate HCV in many cases, and patients die or need
re-transplantation.
The overall SVR rates with PegIFN plus RBV are low; ranging
between 30% and 40% across different series [71,75,76]. These
modest virological results are mainly explained by high rates of
treatment discontinuation (20–38%) and dose reductions (66–
73%) due to adverse events. Liver transplant recipients are prone
to haematological toxicity (particularly anaemia). RBV dose
reductions and the use of erythropoietin (EPO) are very frequent
(75–80%) in this setting [77]. The risk of rejection is small; in the
order of 5% in treated patients [78,79].
Regarding triple therapywith PIs in the post-LT setting, several
studies have evaluated the safety and efﬁcacy of such regimens in
over 300 patients with hepatitis C recurrence [80–82]. Two thirds
of them received telaprevir and the rest were treated with boce-
previr. Most of the patients had an advanced ﬁbrosis stage (META-
VIR FP2) or FCH. Approximately half of the patients had received
a previous course of antiviral therapy. SVR12 rates ranged
between 48% and 62% [80–82]. Despite the increased efﬁcacy,
the major concern of triple therapy in LT recipients is the high rate
of SAEs leading to treatment discontinuation. Drug-drug interac-
tions (DDIs) are an additional challenge when using telaprevir
and boceprevir. First generation PIs are not only substrates, but
also inhibitors of the CYP3A4 system, thus strongly interacting
with many drugs. Due to the narrow therapeutic range of cyclo-
sporine (CsA) and tacrolimus, dose adjustments are crucial and
require very close monitoring when combined with PIs (Table 4).
Data from the only clinical trial assessing the safety and efﬁ-
cacy of telaprevir in the liver transplant setting were presented
at the recent EASL meeting [83]. This was an open-label, single-
arm, study including 20 sites in Europe. Patients with hepatitis
C recurrence, naïve to PR and with a METAVIR score of F0–F3
underwent 12 weeks of triple therapy followed by 36 weeks of
PR. Tacrolimus or cyclosporine doses were adjusted on telaprevir
initiation and discontinuation. Final data from 74 patients
included in the study were available at time of writing this
review and 53 (72%) had achieved SVR12. Nine (12%) patients
had 11 SAEs and no rejection episodes were diagnosed during
the study period.vol. 61 j S120–S131
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Fig. 3. Efﬁcacy results of IFN-based and IFN-free regimens in liver transplant
recipients with hepatitis C recurrence after LT. ⁄Compassionate sofosbuvir use
program including only patients with severe hepatitis C recurrence and a life
expectancy <12 months. O, ombitasvir; D, dasabuvir. PegIFN + RBV [75] and [76];
PegIFN + RBV + PI: SVR12 72% [83]; SVR12 63% [82]; SVR12 50% [81]; SOF/RBV
[84]; SOF/RBV ± PegIFN [85]; ABT450/r/O/D [86].
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Interferon-free regimens after LT
Sofosbuvir and ribavirin
Sofosbuvir and RBV is the ﬁrst interferon-free combination that
has been assessed in hepatitis C recurrence in a clinical trial
[84]. A pilot single-arm study assessed the safety and efﬁcacy
of sofosbuvir 400 mg/d and RBV (dose escalating regimen starting
at 400 mg/d) for 24 weeks in 40 patients with HCV recurrence
(any genotype) at least 6 months after LT.
From the 40 patients, 33 were infected with G1. The study
included treatment-naïve and treatment-experienced patients
(some with PIs); 40% were compensated cirrhotic patients. The
primary efﬁcacy end point was SVR12. Despite these characteris-
tics, all individuals had HCV RNA <25 IU/ml at week 4 of treat-
ment initiation. SVR12 was achieved in 28 (70%) of the 40
patients (Fig 3). Ribavirin dose adjustments did not inﬂuence
SVR. These results can be considered excellent, particularly due
to the good tolerance: most side effects were mild and no rejec-
tion episodes occurred during therapy. Despite the small sample
size and the lack of an interferon-based control arm in the study,
the safety and tolerance proﬁle of this combination seem signif-
icantly better than that of the current standard-of-care.
Results from 104 HCV-infected LT recipients included in the
compassionate use program of sofosbuvir were recently pre-
sented at the EASL meeting (ILC 2014) [85]. The antiviral regimen
included sofosbuvir 400 mg/d for up to 48 weeks, with appropri-
ate doses of RBV. PegIFN was added at the investigator’s discre-
tion. The patients included in this program differed
substantially from those included in the pilot study described
above: approximately half of these patients had severe cholestat-
ic hepatitis (some of them well-documented FCH) or were rapid
ﬁbrosers (METAVIR F P2 one year after LT); the remaining half
had compensated or decompensated cirrhosis. Sixty patients
(58%) presented an improved clinical condition (decrease of
hepatic encephalopathy episodes and/or improvement/disap-
pearance of ascites). Although clinical improvement was assessed
by the investigators (and a bias cannot be ruled out), liver func-
tion tests (bilirubin, albumin, INR) improved remarkably over
time. The other 22 patients (21%) remained stable, while in 22
(21%) the disease progressed or the patient died (n = 18). From
the 93 patients from whom HCV-RNA testing was available at
the end of treatment, 76 (82%) had HCV-RNA below LLOD; 53
(62%) of 85 patients with more than 12 weeks of follow-up after
LT achieved SVR12. Severe adverse events were frequent, but
they were mostly attributed to disease progression. Overall, the
preliminary results of this program indicate that a regimen con-
taining sofosbuvir was able to inhibit hepatitis C replication in
most patients, and that this was associated with an improvement
in the clinical condition in a signiﬁcant number of patients.
Although longer follow-up is needed to assess the rate of SVR
and its impact on disease progression, these results can be con-
sidered very encouraging. A particularly relevant result of this
study was the excellent response in patients with cholestatic
hepatitis (including FCH), in which deeply perturbed laboratory
values (bilirubin, albumin, INR) returned to normal a few weeks
after treatment initiation and viral clearance. SVR12 in patients
with acute cholestatic hepatitis/ﬁbrosing cholestatic hepatitis
was 70%, whereas SVR12 in those with compensated or decom-
pensated cirrhosis points was 40% (Forns, personal communica-
tion). The latter strongly suggests the beneﬁt of early treatment
in severe forms of hepatitis C recurrence.Journal of Hepatology 2014ABT450/r, ombitasvir + dasabuvir and ribavirin in HCV-infected LT
recipients
In this phase 2 study [86] the safety and efﬁcacy of this 3 drug
combination, plus ribavirin administered during 24 weeks, was
assessed in 34 HCV-infected liver transplant patients. The initial
ribavirin dose was decided by the investigators. Individuals were
infected with G1, were naïve after transplantation and had a
METAVIR score 6F2. Based on a previous DDI study, recommen-
dations regarding immunosuppression were to reduce the tacrol-
imus dose by 0.5 mg/week and cyclosporine to 1/5 at time of
antiviral treatment initiation. Preliminary analysis has shown
that all 34 patients had undetectable HCV-RNA at the end of
treatment, and 25 (96%) of 26 with sufﬁcient follow-up achieved
SVR12. The only patient who experienced relapse had RAVs
(R155K in NS3 protease, M28T+Q30R in NS5A, and
G554S+G557R in NS5B); none of these mutations present at base-
line. Tolerance of this regimen was good; no episodes of rejection
were reported.
Other IFN-free regimens
Several clinical trials using different DAA combinations are cur-
rently recruiting patients (Supplementary Table 1). In addition,
analysis of expanded access programs (such as sofosbuvir and
daclatasvir) will also provide relevant practical information in
the next few months [87].
Speciﬁc features of interferon-free regimens in HCV-infected liver
transplant recipients
Treatment with interferon-free regimens in patients with hepati-
tis C recurrence is challenging for several reasons. Treatment may
be indicated in individuals with very aggressive forms of hepatitis
C (such as FCH), which occur very early after transplantation. The
latter poses several difﬁculties, since at this early period individ-
uals are still under strong immunosuppression, at risk of oppor-
tunistic infections, not uncommonly recovering or being treated
from surgical complications and undergoing treatment with mul-
tiple drugs. Fortunately, many new anti-HCV compounds do not
seem to have clinically signiﬁcant interactions with CsA and
tacrolimus (Table 4).vol. 61 j S120–S131 S127
After liver transplantation Waiting list  
SOF + RBV (± PegIFNα)
SOF/DCV + RBV   
Awaiting data from
clinical trials
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EAP or clinical trials  
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SOF/LDV + RBV#
Compassionate use/EAP
or clinical trials
No indication for 
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Fig. 4. Therapeutic approaches of HCV infection in 3 different patient populations: cirrhotic patients with decompensated disease without the indication of LT,
patients on waiting list for LT and liver transplant recipients with hepatitis C recurrence after LT. #Only GT1,4; ⁄only GT1,4–6; ¥only GT1 (pending regulatory
approval); EAP, expanded access program; O, ombitasvir; D, dasabuvir. § Very few data are available at this time.
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Journal of Hepatology Update: Hepatitis CRenal failure is also common in liver transplant recipients.
Most patients have decreased glomerular ﬁltration rate (GFR)
due (at least in part) to the long-term use of cyclosporine or
tacrolimus. Sofosbuvir, for instance, is not recommended if GFR
is below 30 ml/min [88].
An issue that needs particular consideration in the liver trans-
plant setting is that these patients usually have high viral loads,
making it easier to select for drug resistant strains. The latter
might be particularly relevant in patients with FCH.Treating before or after liver transplantation?
The negative impact of hepatitis C infection on liver transplant
recipients is well known. With a progressive increase in the age
of the donors in recent years [89–91], the proportion of patients
with severe forms of hepatitis C recurrence has increased and
these patients will require antiviral treatment [47,73,92]. Fur-
thermore, they will have a complex follow-up and consume a
lot of resources: in most cases differential diagnosis from other
frequent pathologies (such as rejection) is not easy. Adjustment
of immunosuppressive drugs is complicated and patients often
require hospitalization. Thus, from a theoretical point of view,
treatment before transplantation seems ideal, because it may
substantially improve the post-transplant course, it may increase
survival, and in some cases viral clearance may be associated
with liver function improvement and delisting (important in a
context of organ shortage). However, before this strategy can be
implemented in clinical practice, we need data on the safety
and efﬁcacy of interferon-free regimens in patients with decom-
pensated cirrhosis and data on the impact of viral clearance on
liver function. Furthermore, the time on waiting list for complet-
ing antiviral therapy is usually unpredictable.
There are a number of patients who have already developed
graft damage following transplantation and for whom the only
choice in the coming years will be interferon-free regimens.
These patients include individuals with early severe recurrence
after transplantation, non-responders and intolerant-to-
interferon-based regimens, and patients with decompensatedS128 Journal of Hepatology 2014cirrhosis. In the latter group, viral clearance in individuals with
high MELD scores might permit considering them for retrans-
plantation [93].
We will probably start answering all these questions in the
next months, when real-life data and results from ongoing clini-
cal trials will gather relevant information that will help us choose
the best choice for each patient. Meanwhile, a suggested
approach to these difﬁcult-to-treat patients is shown in Fig 4.Financial support
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